Our findings therefore do not lessen the importance of CCR8 as a potential target in therapies aimed at selectively targeting tumour‐associated Treg cells, but suggest that therapeutic depletion of CCR8+ Treg cells rather than blockade of CCR8 function is likely to be more efficacious. Here, CCR8 is linked to neoplasm.